Hyperferritinemia in the elderly can differentiate the bad from the worst: A retrospective cohort analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
31 Jul 2020
31 Jul 2020
Historique:
entrez:
7
8
2020
pubmed:
7
8
2020
medline:
19
8
2020
Statut:
ppublish
Résumé
Both total-body iron stores and inflammation influence the concentration of ferritin in the blood. Ferritin as an inflammatory marker might serve as a prognostic marker in the elderly. Therefore, we characterized the clinical circumstances and long-term outcomes of hyperferritinemia (> 1000 μg/L) in hospitalized elderly patients.A retrospective analysis of elderly (> 70 years) inpatients with ferritin levels of > 1000 μg/L in a tertiary medical center during a 3-year period. We obtained both laboratory and clinical data, assessing the potential association of high ferritin levels with long-term mortality.Overall, 242 patients (median age 79 years; median ferritin level 1436 μg/L) met the inclusion criteria and were followed for a median time of 18.6 months. Clinical outcomes were dismal for the whole cohort: the diagnosis of solid malignancy occurred in 23.5% of cases while 31% had a severe infection (ranging from sepsis to septic shock). The median survival time of the whole cohort was 4.7 months only. Within the cohort, risk stratification was feasible: higher ferritin levels differentiate between groups of patients who had a poor prognosis (with either septic shock or solid malignancy) and those who had a relatively favorable prognosis (patients diagnosed as suffering from sepsis without shock and patients with iatrogenic causes for hyperferritinemia).Hyperferritinemia in elderly inpatients is associated with high rates of mortality. Within this group of patients, differential ferritin levels enable further risk stratification. High ferritin levels in the elderly can differentiate the bad from the worst.
Identifiants
pubmed: 32756143
doi: 10.1097/MD.0000000000021419
pii: 00005792-202007310-00073
pmc: PMC7402730
doi:
Substances chimiques
Biomarkers
0
Ferritins
9007-73-2
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e21419Références
Ann Epidemiol. 2000 Oct;10(7):441-8
pubmed: 11023623
J Clin Rheumatol. 2013 Sep;19(6):324-8
pubmed: 23965472
Eur J Endocrinol. 2013 Jul 13;169(2):247-53
pubmed: 23715774
Leukemia. 2008 Mar;22(3):538-43
pubmed: 18079733
Nephron. 1993;64(1):95-100
pubmed: 8502343
BMC Med. 2013 Aug 22;11:185
pubmed: 23968282
South Med J. 2015 Sep;108(9):574-8
pubmed: 26332484
Int J Epidemiol. 1998 Oct;27(5):799-807
pubmed: 9839736
Int J Clin Exp Med. 2015 Aug 15;8(8):13317-22
pubmed: 26550259
Int Immunol. 2018 Apr 25;30(5):195-203
pubmed: 29420734
Best Pract Res Clin Rheumatol. 2018 Oct;32(5):662-668
pubmed: 31203924
Biochim Biophys Acta. 2010 Aug;1800(8):760-9
pubmed: 20304033
Blood. 2015 Mar 5;125(10):1548-52
pubmed: 25573993
Haematologica. 2004 Oct;89(10):1187-93
pubmed: 15477202
Clin Invest Med. 2005 Apr;28(2):48-54
pubmed: 15909479
Diabetes Care. 2013 Dec;36(12):4147-56
pubmed: 24130349
QJM. 2014 Aug;107(8):623-33
pubmed: 24599805
Clin Chem. 2014 Nov;60(11):1419-28
pubmed: 25156997
J Autoimmun. 2018 Sep;93:24-36
pubmed: 30077425
Nutr Metab Cardiovasc Dis. 2012 Sep;22(9):734-40
pubmed: 21330119
Presse Med. 2013 Apr;42(4 Pt 1):405-10
pubmed: 22795836
Dis Markers. 2013;34(3):211-8
pubmed: 23324584
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
Am J Clin Nutr. 1974 Jul;27(7):681-7
pubmed: 4472911